Related Experiment Video
Updated: Feb 26, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Pneumococcal conjugate vaccine implementation in middle-income countries
Serena Tricarico1,2,3, Hannah C McNeil1,2,3, David W Cleary1,2
1Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Middle-income countries (MICs) face challenges in adopting pneumococcal conjugate vaccines (PCVs), hindering pneumonia prevention. Addressing financial aid, data gaps, and cost is crucial for wider PCV implementation and reducing disease burden.
Area of Science:
- Public Health
- Vaccinology
- Global Health Policy
Background:
- Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumonia since 2000.
- Middle-income countries (MICs) lag in PCV adoption due to limited international financial support.
- This review examines PCV implementation status, needs, and solutions in MICs.
Purpose of the Study:
- To review the current status of pneumococcal conjugate vaccine (PCV) implementation in middle-income countries (MICs).
- To identify barriers and gaps hindering widespread PCV use in MICs.
- To analyze potential solutions for strengthening PCV implementation in MICs.
Main Methods:
- Systematic review of literature from PubMed, PubMed Central, Ovid MEDLINE, and SCOPUS.
- Inclusion criteria focused on pneumococcal immunization, health policy, and MICs.
- Eight articles were included after assessing 1,165 initial search results.
Main Results:
- MICs exhibit slower PCV uptake compared to low-income and high-income countries.
- GAVI "graduation" and loss of financial assistance impact uptake, especially in lower middle-income countries (LMICs).
- Key barriers include lack of disease burden data, limited local economic evaluation expertise, and high PCV costs.
Conclusions:
- Global recognition of impediments to vaccine introduction in MICs is essential.
- Enhanced PCV access in MICs can decrease pneumonia incidence.
- Improved PCV use may reduce antimicrobial resistance selection pressure.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Primary Healthcare Services
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...